Precigen/$PGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precigen
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Ticker
$PGEN
Sector
Primary listing
Employees
160
Headquarters
Website
Precigen Metrics
BasicAdvanced
$1.6bn
-
-$1.17
1.07
-
Price and volume
Market cap
$1.6bn
Beta
1.07
52-week high
$5.47
52-week low
$1.28
Average daily volume
3.2m
Financial strength
Current ratio
4.818
Quick ratio
3.931
Long term debt to equity
480.267
Total debt to equity
485.545
Interest coverage (TTM)
-13.29%
Profitability
EBITDA (TTM)
-86.329
Gross margin (TTM)
-35.39%
Net profit margin (TTM)
-646.99%
Operating margin (TTM)
-284.85%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-42.07%
Return on equity (TTM)
-1,145.42%
Valuation
Price to revenue (TTM)
45.898
Price to book
77.74
Price to tangible book (TTM)
735.44
Price to free cash flow (TTM)
-12.398
Free cash flow yield (TTM)
-8.07%
Free cash flow per share (TTM)
-0.357
Growth
Revenue change (TTM)
652.08%
Earnings per share change (TTM)
108.06%
3-year revenue growth (CAGR)
10.77%
10-year revenue growth (CAGR)
-16.12%
3-year earnings per share growth (CAGR)
113.88%
10-year earnings per share growth (CAGR)
-2.77%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Precigen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precigen stock?
Precigen (PGEN) has a market cap of $1.6B as of May 18, 2026.
What is the P/E ratio for Precigen stock?
The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of May 18, 2026.
Does Precigen stock pay dividends?
No, Precigen (PGEN) stock does not pay dividends to its shareholders as of May 18, 2026.
When is the next Precigen dividend payment date?
Precigen (PGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Precigen?
Precigen (PGEN) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.